A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Mark Hamblin

Intermune, Inc.

An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Mark Hamblin

Intermune, Inc.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis

Mark Hamblin

Fibrogen, Inc.

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis

Mark Hamblin

Genentech-Roche, Inc.

Randomized, Double-Blind, Placebo-Controlled,Multiple Dose, Dose-Escalation Study of STX-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Mark Hamblin

Biogen MA Inc.

A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Mark Hamblin

Intermune, Inc.

A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Mark Hamblin

Promedior, Inc.

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease(SSc-ILD).

Mark Hamblin

Boehringer Ingelheim 

A Phase II randomized, double-blind, placebo-controlled study of GBT440 to evaluate the safety, tolerability, pharmacokinetics and effect on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF)

Mark Hamblin

Global Blood Therapeutics

PFF Patient Registry Protocol

Mark Hamblin

University of Michigan 

A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

Lucas Pitts

Boehringer Ingelheim 

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Lucas Pitts

Boehringer Ingelheim 

An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) SENSCIS-ON

Mark Hamblin

Boehringer Ingelheim 

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis

Mark Hamblin

Biogen MA Inc.

Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF)

Mark Hamblin

NIH/NHLBI

A Phase 5 Multicenter, Randomized, Double Blind, Placebo-Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects with Pulmonary Sarcoidosis

Mark Hamblin

Mallinckrodt Pharmaceuticals

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

Mark Hamblin

Galapagos

An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Lucas Pitts

Fibrogen, Inc.

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally

Mark Hamblin

Boehringer Ingelheim